Amgen third quarter sales rise 8%, led by cholesterol, cancer drugs

2

* Adjusted EPS rises 14% to $6.45 * 2026 EPS outlook raised to $22.90 to $23.70 on revenue ⁠of $38.9 billion to $39.7 billion By Deena Beasley Nov 3 (Reuters) – Amgen on Tuesday said third-quarter

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)